THR-β modulator-3 (Compound 75-2) is a THR-β modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity.

Thioaspirine is a carbonic anhydrase (CA) inhibitor with Kis of 64.3 and 10.9 μM for hCA II and hCA IX, respectively. Thioaspirine effectively relieves the inflammatory pain in CFA-treated mice. Thioaspirine can be used for inflammatory pain research.

Thalidomide-azetidine-COOH is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.

Thalidomide-5-NH-C9-acid is a synthetic E3 ligase ligand-linker conjugate containing a Thalidomide-based Cereblon ligand and one linker.

Thalidomide-5-F-6-piperidinylpiperazin is an ligands for E3 ligase-linker conjugate, which is used for the synthesis of PROTAC CDK9 degrader-9.

Thalidomide-4-O-C9-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and a linker used in PROTAC technology. Thalidomide-4-O-C9-Br can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-19.

Thalidomide-4-O-C11-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and a linker used in PROTAC technology. Thalidomide-4-O-C11-Br can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-23.

TGR5 agonist 10 is a selective, allosteric and orally active Takeda G protein coupled receptor 5 (TGR5) agonist with EC50s of 0.8 μM and 0.6 μM for human TGR5 and mouse TGR5, respectively. TGR5 agonist 10 demonstrates selectivity for TGR5 over FXR. TGR5 agonist 10 activates hTGR5 and mTGR5 to induce cAMP accumulation, and positively modulates lithocholic acid functional activity and potency at hTGR5, with higher selectivity for cAMP formation over β-arrestin2 recruitment. TGR5 agonist 10 exerts glucose-lowering effects in Mus musculus oral glucose tolerance tests. TGR5 agonist 10 can be used for the research of diabetes.

TGF-β/Smad-IN-3 (Compound 4w) is an effective TGF-β/Smad inhibitor. TGF-β/Smad-IN-3 exerts anti-pulmonary fibrosis activity by simultaneously inhibiting the TGF-β/Smad and MAPK signaling pathways. TGF-β/Smad-IN-3 significantly inhibits collagen deposition induced by TGF-β1, with its IC50 value being 3.21 μM. TGF-β/Smad-IN-3 has an IC₅₀ of 46.77 nM for the autocrine motility factor (ATX). TGF-β/Smad-IN-3 significantly reduces the expression levels of α-SMA, COL1A1 and FN in TGF-β1-induced CCC-HPF-1 cells, and effectively inhibited TGF-β1-induced cell migration. TGF-β/Smad-IN-3 can be used for the study of pulmonary fibrosis.

TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate for ADC. TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT consists of a topoisomerase 1 inhibitor (Topi MF-6) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala). TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT can be used for synthesis of ADCs.

Tezampanel (LY293558) hydrate is a potent, selective and competitive NMDA receptor antagonist. Tezampanel hydrate produces postoperative analgesia in rats. Tezampanel hydrate can be used for neuropathic pain research.

tert-Butyl N-methyl-N-(piperidin-4-ylmethyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl N-(2-azaspiro[3.3]heptan-6-yl)carbamate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(methylamino)butylcarbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(azetidin-3-yl)piperazine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(3-hydroxypropyl)tetrahydropyridine-1(2H)-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 3-cyanoazetidine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-butyl (5-bromopentyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl (3-(methylamino)propyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl (2-(azetidin-3-yl)ethyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

Ternidazole is a 2-methyl-5-nitroimidazole derivative and an antiprotozoal agent. Ternidazole exhibits antiprotozoal properties and is found to be effective against chronic alcoholism.

Terfenadine N-oxide, an N-oxide derivative of Terfenadine, is a histamine H1 receptor antagonist (IC50 = 2.73 μM) and an hERG potassium channel inhibitor (IC50 = 0.698 μM). Terfenadine N-oxide is can be used for the research of histamine-related allergic diseases and hERG channel-associated arrhythmias.

Terbequinil (SR-25776) is a potent orally active Gamma-aminobutyric acid A (GABAA) receptor inverse agonist. Terbequinil can be used for research on nervous system diseases.

Terazosin-md (compound TZ-md), a derivative of both Alfuzosin and Terazosin, is an orally active α1-adrenergic receptor antagonist. Terazosin-md has the functions of improving mitochondrial metabolism, degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin-md shows effect in a mouse model with Alzheimer's disease. Terazosin-md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders.

Tenivastatin calcium is a HMG-CoA reductase inhibitor. Tenivastatin calcium can reduce blood lipid level can be used for the research of hyperlipidemia.

Telomeric G4s ligand 2 is an orally active, selective ligand of telomeric G-quadruplex (G4), with an IC50 of 0.4 μM. Telomeric G4s ligand 2 binds to dimeric telomeric G4, inhibits the activities of DHX36 and BLM helicases. Telomeric G4s ligand 2 activates cGAS-STING and TERRA-ZBP1 pathways, inducing autophagy and G2/M cell cycle arrest, and exhibits antiproliferative effects across cancer cell lines. Telomeric G4s ligand 2 can be used for the study of colorectal cancer.